Patient characteristics
Characteristic . | Newly diagnosed . | Relapsed . | Long-term remission . |
|---|---|---|---|
| Total no. of patients | 41 | 9 | 43 |
| Sex, F/M | 14/27 | 5/4 | 17/26 |
| Mean age at diagnosis, y | 31 | 41 | 30 |
| Clinical stage IIB/III/IV, no. (%) | 20 (49) | 5 (66) | Not applicable |
| Prognostic score 3 or more*, no. (%) | 12 (29) | 4 (44) | Not applicable |
| Timing of blood sample(s) | Prior to therapy, 6 mo, 12 mo | Prior to therapy, 6 mo, 12 mo | Mean, 5 y; range, 2-33 y after diagnosis |
| Histology†, no. of total (%) | |||
| Nodular sclerosing | 27/41 (66) | 7/9 (78) | 18/36 (50) |
| Mixed cellularity | 7/41 (17) | 1/9 (11) | 6/36 (17) |
| Lymphocyte rich | 4/41 (10) | 0/9 (0) | 4/36 (11) |
| Lymphocyte depleted | 1/41 (2) | 0/9 (0) | 1/36 (3) |
| Nodular lymphocyte predominant | 2/41 (5) | 1/9 (11) | 3/36 (8) |
| Unclassified Hodgkin | 0/41 (0) | 0/9 (0) | 4/36 (11) |
| Positive EBV serology‡, no. of total (%) | 39/40 (98) | 8/9 (89) | 40/43 (93) |
| Positive EBV tissue status§, no. of total (%) | 15/41 (36) | 1/9 (11) | 9/27 (33) |
Characteristic . | Newly diagnosed . | Relapsed . | Long-term remission . |
|---|---|---|---|
| Total no. of patients | 41 | 9 | 43 |
| Sex, F/M | 14/27 | 5/4 | 17/26 |
| Mean age at diagnosis, y | 31 | 41 | 30 |
| Clinical stage IIB/III/IV, no. (%) | 20 (49) | 5 (66) | Not applicable |
| Prognostic score 3 or more*, no. (%) | 12 (29) | 4 (44) | Not applicable |
| Timing of blood sample(s) | Prior to therapy, 6 mo, 12 mo | Prior to therapy, 6 mo, 12 mo | Mean, 5 y; range, 2-33 y after diagnosis |
| Histology†, no. of total (%) | |||
| Nodular sclerosing | 27/41 (66) | 7/9 (78) | 18/36 (50) |
| Mixed cellularity | 7/41 (17) | 1/9 (11) | 6/36 (17) |
| Lymphocyte rich | 4/41 (10) | 0/9 (0) | 4/36 (11) |
| Lymphocyte depleted | 1/41 (2) | 0/9 (0) | 1/36 (3) |
| Nodular lymphocyte predominant | 2/41 (5) | 1/9 (11) | 3/36 (8) |
| Unclassified Hodgkin | 0/41 (0) | 0/9 (0) | 4/36 (11) |
| Positive EBV serology‡, no. of total (%) | 39/40 (98) | 8/9 (89) | 40/43 (93) |
| Positive EBV tissue status§, no. of total (%) | 15/41 (36) | 1/9 (11) | 9/27 (33) |
Hasenclever/Diehl International Prognostic Score.
Histology available in all newly diagnosed and relapsed cases and 36 of 43 (84%) remission cases.
Serology undetermined in 1 newly diagnosed case.
Biopsy available for EBV testing in all newly diagnosed and relapsed cases and 27 of 43 (63%) remission cases. EBV tissue status correlated with histology, with 55% of mixed cellularity or lymphocyte-rich cases positive for EBV, against 27% of nodular sclerosing cases (r = 0.38, P = .013). In 2 of 67 cases the LMP1 and EBER stains were discordant (EBER positive/LMP1 negative). Both cases were classified as EBV tissue positive.